Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply

Rheumatology (Oxford). 2022 Aug 3;61(8):e238-e239. doi: 10.1093/rheumatology/keac158.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Arthritis, Psoriatic* / chemically induced
  • Arthritis, Psoriatic* / drug therapy
  • Biological Products* / adverse effects
  • Cardiovascular Diseases* / chemically induced
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / epidemiology
  • Cohort Studies
  • Humans
  • Psoriasis* / drug therapy
  • Thalidomide / analogs & derivatives

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Biological Products
  • Thalidomide
  • apremilast